NASDAQ:LNTH - Nasdaq - US5165441032 - Common Stock - Currency: USD
NASDAQ:LNTH (5/21/2025, 3:32:56 PM)
75.145
-1.69 (-2.19%)
The current stock price of LNTH is 75.145 USD. In the past month the price decreased by -22.84%. In the past year, price decreased by -1.78%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ALC | ALCON INC | 28.71 | 43.76B | ||
COO | COOPER COS INC/THE | 21.08 | 15.89B | ||
ALGN | ALIGN TECHNOLOGY INC | 18.44 | 12.59B | ||
SOLV | SOLVENTUM CORP | 12.21 | 12.57B | ||
MMSI | MERIT MEDICAL SYSTEMS INC | 27.05 | 5.71B | ||
BLCO | BAUSCH + LOMB CORP | 23.51 | 3.99B | ||
HAE | HAEMONETICS CORP/MASS | 14.63 | 3.36B | ||
ICUI | ICU MEDICAL INC | 18.65 | 3.20B | ||
XRAY | DENTSPLY SIRONA INC | 9.46 | 3.17B | ||
UFPT | UFP TECHNOLOGIES INC | 27.83 | 1.75B | ||
NEOG | NEOGEN CORP | 16.3 | 1.34B | ||
ESTA | ESTABLISHMENT LABS HOLDINGS | N/A | 1.04B |
Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The company is headquartered in North Billerica, Massachusetts and currently employs 808 full-time employees. The company went IPO on 2015-06-25. The company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, others. Its OCTEVY is a registrational-stage positron emission tomography (PET) diagnostic imaging agent targeting neuroendocrine tumors.
LANTHEUS HOLDINGS INC
331 Treble Cove Rd
North Billerica MASSACHUSETTS 01862 US
CEO: Mary Anne Heino
Employees: 808
Phone: 19786718001
The current stock price of LNTH is 75.145 USD. The price decreased by -2.19% in the last trading session.
The exchange symbol of LANTHEUS HOLDINGS INC is LNTH and it is listed on the Nasdaq exchange.
LNTH stock is listed on the Nasdaq exchange.
19 analysts have analysed LNTH and the average price target is 137.62 USD. This implies a price increase of 83.14% is expected in the next year compared to the current price of 75.145. Check the LANTHEUS HOLDINGS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
LANTHEUS HOLDINGS INC (LNTH) has a market capitalization of 5.15B USD. This makes LNTH a Mid Cap stock.
LANTHEUS HOLDINGS INC (LNTH) currently has 808 employees.
LANTHEUS HOLDINGS INC (LNTH) has a support level at 76.82 and a resistance level at 76.83. Check the full technical report for a detailed analysis of LNTH support and resistance levels.
The Revenue of LANTHEUS HOLDINGS INC (LNTH) is expected to grow by 3.55% in the next year. Check the estimates tab for more information on the LNTH EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
LNTH does not pay a dividend.
LANTHEUS HOLDINGS INC (LNTH) will report earnings on 2025-07-29, before the market open.
The PE ratio for LANTHEUS HOLDINGS INC (LNTH) is 11.35. This is based on the reported non-GAAP earnings per share of 6.62 and the current share price of 75.145 USD. Check the full fundamental report for a full analysis of the valuation metrics for LNTH.
The outstanding short interest for LANTHEUS HOLDINGS INC (LNTH) is 10.33% of its float. Check the ownership tab for more information on the LNTH short interest.
ChartMill assigns a technical rating of 1 / 10 to LNTH. When comparing the yearly performance of all stocks, LNTH turns out to be only a medium performer in the overall market: it outperformed 41.49% of all stocks.
ChartMill assigns a fundamental rating of 8 / 10 to LNTH. LNTH has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
Over the last trailing twelve months LNTH reported a non-GAAP Earnings per Share(EPS) of 6.62. The EPS increased by 2.64% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 16.55% | ||
ROA | 12.37% | ||
ROE | 21.85% | ||
Debt/Equity | 0.49 |
ChartMill assigns a Buy % Consensus number of 82% to LNTH. The Buy consensus is the average rating of analysts ratings from 19 analysts.
For the next year, analysts expect an EPS growth of 0.63% and a revenue growth 3.55% for LNTH